Biotech Leaders to Confront Industry Issues at Milan Conference March 5-7, 2007.Topics at BIO-Europe Spring to include globalization globalization Process by which the experience of everyday life, marked by the diffusion of commodities and ideas, is becoming standardized around the world. Factors that have contributed to globalization include increasingly sophisticated communications and transportation , new financing models, scientific trends and M&A trends CARLSBAD, Calif. & MUNICH, Germany -- EBD EBD Emotional or behavioral disorder Group today announced that on Monday, March 5, international biotechnology industry leaders will descend on Milan, Italy, for BIO-Europe Spring (March 5-7) to discuss and analyze the market, new business approaches, scientific developments and policy trends that will shape the biotechnology of the future. On Monday, March 5, at the Milano Conference Center, some of the most respected names in the industry will confront hot current issues. Highlights of the day will include: * Rethinking the Biotech-Pharma Partnering Model: Will the whole ever be worth more than the sum of its parts? A plenary session Plenary session is a term often used in s to define the part of the conference when all members of all parties are in attendance. These sessions may contain a broad range of content from Keynotes to Panel Discussions and are not necessarily related to a specific style of delivery. exploring whether the current explosion of M&A deals is sustainable and how it will impact drug development. Will new drugs reach the marketplace sooner if smaller firms exit the process earlier and earlier? Moderated by Roger Longman, Managing Partner, Windhover wind·hov·er n. Chiefly British A kestrel. Information, the plenary panel will feature Robert I Robert I, duke of Normandy Robert I (Robert the Magnificent), d. 1035, duke of Normandy (1027–35); father of William the Conqueror. He is often identified with the legendary Robert the Devil. . Blum, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Cytokinetics, Inc.; Dr. Judith Hills, Corporate and Business Development, VP, Licensing, Europe, Japan & Asia Pacific, Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were ; Louis J. Scotti, VP, Marketing and Business Development, Arena Pharmaceuticals, Inc.; Rob Wills, VP, Alliance Management, Johnson & Johnson. * Financing Innovation - The View of Entrepreneurs and VCs. A panel considering whether traditional VC models will remain affordable and exploring new modes of financing biotechnology innovation. With moderator Ian Nicholson, CEO, Chroma Short for "chrominance." The attributes of a color, which include its hue (frequency) and saturation (amount of black). See hue and saturation. Therapeutics and panelists Joel Besse, Partner, Atlas Venture; Dr. Francesco De Rubertis, Partner Life Sciences, Index Ventures Management; Dr. Claudio Semeraro, CEO, Z-Cube, and Dr. Francesco Sinigaglia, CEO, BioXell. * The Globalizing of Biotech Dealmaking. A panel examining how biotech entrepreneurs are leveraging the cost and regulatory advantages that exist outside of Europe and the US, for example what are the new types of transactions and alliances that can enhance access to capital, technology, markets, and drug development expertise on a global basis With moderator Dr. Simba Gill, CEO, moksha Moksha (môk`shə), river, c.375 mi (600 km) long, rising NW of Penza, central European Russia, and flowing generally NW into the Oka River. Its lower course is navigable. 8 and Venture Partner, Entrepreneur in Residence An Entrepreneur In Residence (EIR) is an entrepreneur who partners with a venture fund.. EIR A role as an entrepreneur in residence (EIR) with a venture fund is a very coveted role for many entrepreneurs. , TPG TPG Texas Pacific Group TPG Tapping TPG Transports Publics Genevois (Geneva, Switzerland public transportation) TPG Test Pattern Generator TPG TNT Post Group TPG Trésorier Payeur Général Growth and panelists Hans Peter Hasler, Senior VP, Head of International, Biogen Idec; Gardiner Smith, Advisor, SHI Link; Dr. Greg Wiederrecht, VP, External Scientific Affairs, Merck & Co., Inc. * The Combination of White and Red Biotechnologies. A discussion of achievements and developments in the exciting new field of "white" - or industrial biotech - expected to be a major source of new products, and its convergence with "red" - or medical biotech. With Martin Austin, Managing Director,TransformRX; Fran[?]ois Arcand, CEO, ERA Biotech; SA, Camille Burel, Industrial Biotech Project Administrator, EuropaBio; James C. Greenwood James Charles (Jim) Greenwood (born May 4, 1951) represented Pennsylvania's Eighth Congressional District for six terms in the United States House of Representatives as a Republican. Greenwood was born in Philadelphia, Pennsylvania and grew up in Holland, Pennsylvania. , President & CEO, Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
Other workshops and panels featured on Monday, March 5, are: * Biocatalysis - Biology Catalysing Chemistry - Does It Work? * Licensing and Strategic Alliances: How to Get Married and Avoid an Ugly Divorce * A Different Perspective on Alliances: Partnerships with Research Tools and Service Companies as a Mechanism to Build Value in Early Stage Biotechs * Biotech to Biotech Deals - How does Big Pharma look at these Collaborations? * Size Isn't Everything - Can Mid-Size Pharma Compete For The Best In-Licensing Opportunities? * Cancer Therapeutic Session * What is Next in the Antibody Space? * Infectious Diseases Therapeutic Session * CNS See Continuous net settlement. CNS See continuous net settlement (CNS). Therapeutic Session * Biotechnology in Italy 2007: A financial and strategic Analysis A complete list of workshops, panels and abstracts can be accessed at: http://www.ebdgroup.com/bes/ws_panels.htm Notes to Editors: Entry to BIO-Europe Spring is free to the media, as is full access to the partnering system, sessions, press conferences, workshops, and pre-arranged partnering meetings. Visit the BIO-Europe Spring conference website at http://www.ebdgroup.com/bes/registration.htm for detailed information on this year's conference and online registration. When you register online, please write into the comment field within the registration form that you are requesting a complimentary press registration. Please fax a copy of your press pass to complete your complimentary media registration to fax number +49 (89) 23 88 756 - 55. About EBD Group EBD Group is the leading partnering firm for the global biotechnology industry. Since 1993, firms in the life sciences have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships that drive their business. EBD Group's conferences (run in collaboration with leading industry partners and international trade associations such as BIO and Eucomed) include BIO-Europe, the world's largest stand-alone life science partnering conference; BIO-Europe Spring; the investor conference, BioEquity Europe (co-organized with BioCentury Publications); and the convergent medical technology partnering conference, BioDevice Partnering. EBD's novel, web-based, partnering software system is also used at numerous third-party events around the world. Outside of the conference format, EBD Group's consultants can provide hands-on assistance for firms seeking to in- or out-license products and technologies. EBD Group has offices in San Diego, Munich and London. For more information visit www.ebdgroup.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion